Last reviewed · How we verify
misoprostol 800 mcg
Misoprostol 800 mcg, marketed by Hany Farouk, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and revenue generation, though specific figures are not disclosed. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | misoprostol 800 mcg |
|---|---|
| Also known as | Active Comparator |
| Sponsor | hany farouk |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy (PHASE4)
- Letrozole Plus Misoprostol Versus Misoprostol Alone for Treating Women With Missed Miscarriage (PHASE4)
- Letrozole and Misoprostol for Early Pregnancy Loss Management (PHASE2)
- Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy (EARLY_PHASE1)
- Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage (NA)
- Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone (NA)
- Mail Order Mifepristone Study (PHASE4)
- Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- misoprostol 800 mcg CI brief — competitive landscape report
- misoprostol 800 mcg updates RSS · CI watch RSS
- hany farouk portfolio CI